Cargando…
Off-label use of rituximab in systemic lupus erythematosus: a systematic review
Considerable interest in the efficacy of rituximab (a monoclonal CD20 antibody) in patients with systemic lupus erythematosus (SLE) has been generated due to its unique mode of action, culminating in a series of randomized and open trials, and case reports. However, this use is off-license and two s...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer-Verlag
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102216/ https://www.ncbi.nlm.nih.gov/pubmed/20155295 http://dx.doi.org/10.1007/s10067-010-1387-5 |